LQDA logo

Liquidia (LQDA) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

26 July 2018

Indexes:

Not included

Description:

Liquidia is a biopharmaceutical company focused on developing innovative treatments for serious diseases. They use their proprietary technology to create advanced drug formulations, particularly in respiratory and rare diseases, aiming to improve patient outcomes and enhance the effectiveness of existing therapies.

Key Details

Price

$11.70

Annual Revenue

$17.49 M(+9.75% YoY)

Annual EPS

-$1.21(-80.60% YoY)

Annual ROE

-114.01%

Beta

0.40

Events Calendar

Earnings

Next earnings date:

Mar 13, 2025

Recent quarterly earnings:

Nov 11, 2024

Recent annual earnings:

Mar 13, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

16 Oct '24 Scotiabank
Sector Outperform
03 Oct '24 LifeSci Capital
Outperform
23 Aug '24 HC Wainwright & Co.
Buy
22 Aug '24 Needham
Buy
20 Aug '24 HC Wainwright & Co.
Buy
20 Aug '24 BTIG
Buy
20 Aug '24 B of A Securities
Buy
19 Aug '24 Raymond James
Strong Buy
19 Aug '24 Needham
Buy
19 Aug '24 BTIG
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Liquidia Corporation: Resilience In The Face Of Formidable Opposition Can Pay Off
Liquidia Corporation: Resilience In The Face Of Formidable Opposition Can Pay Off
Liquidia Corporation: Resilience In The Face Of Formidable Opposition Can Pay Off
LQDA
seekingalpha.com15 November 2024

Liquidia's Yutrepia, a competitor to United Therapeutics' Tyvaso, faces potential market entry in 2025, with promising clinical data and a competitive therapeutic profile. Despite financial challenges and intense competition, Liquidia's low valuation and upcoming product launches present a compelling investment opportunity. Liquidia's legal battles with United Therapeutics are nearing resolution, potentially clearing the path for Yutrepia's commercial launch by mid-2025.

Liquidia Corporation (LQDA) Q3 2024 Earnings Call Transcript
Liquidia Corporation (LQDA) Q3 2024 Earnings Call Transcript
Liquidia Corporation (LQDA) Q3 2024 Earnings Call Transcript
LQDA
seekingalpha.com13 November 2024

Liquidia Corporation (NASDAQ:LQDA ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Roger Jeffs - Chief Executive Officer Rusty Schundler - General Counsel Rajeev Saggar - Chief Medical Officer Michael Kaseta - Chief Operating Officer & Chief Financial Officer Scott Moomaw - Chief Commercial Officer Conference Call Participants Julian Harrison - BTIG Jason Gerberry - Bank of America Greg Harrison - Scotiabank Kambiz Yazdi - Jefferies Cory Jubinville - LifeSci Capital Matt Kaplan - Ladenburg Thalmann Ryan Deschner - Raymond James Operator Good morning and welcome everyone to Liquidia Corporation Third Quarter 2024 Financial Results and Corporate Update Conference Call. My name is Michelle [ph] and I will be your conference operator today.

Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates
Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates
Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates
LQDA
zacks.com13 November 2024

Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.37 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.24 per share a year ago.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
LQDA
prnewswire.com02 November 2024

NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
LQDA
accesswire.com31 October 2024

NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
LQDA
accesswire.com27 October 2024

NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
LQDA
prnewswire.com25 October 2024

NEW YORK , Oct. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
LQDA
prnewswire.com17 October 2024

NEW YORK , Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
LQDA
accesswire.com15 October 2024

NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
LQDA
accesswire.com13 October 2024

NEW YORK, NY / ACCESSWIRE / October 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

FAQ

  • What is the primary business of Liquidia?
  • What is the ticker symbol for Liquidia?
  • Does Liquidia pay dividends?
  • What sector is Liquidia in?
  • What industry is Liquidia in?
  • What country is Liquidia based in?
  • When did Liquidia go public?
  • Is Liquidia in the S&P 500?
  • Is Liquidia in the NASDAQ 100?
  • Is Liquidia in the Dow Jones?
  • When was Liquidia's last earnings report?
  • When does Liquidia report earnings?
  • Should I buy Liquidia stock now?

What is the primary business of Liquidia?

Liquidia is a biopharmaceutical company focused on developing innovative treatments for serious diseases. They use their proprietary technology to create advanced drug formulations, particularly in respiratory and rare diseases, aiming to improve patient outcomes and enhance the effectiveness of existing therapies.

What is the ticker symbol for Liquidia?

The ticker symbol for Liquidia is NASDAQ:LQDA

Does Liquidia pay dividends?

No, Liquidia does not pay dividends

What sector is Liquidia in?

Liquidia is in the Healthcare sector

What industry is Liquidia in?

Liquidia is in the Biotechnology industry

What country is Liquidia based in?

Liquidia is headquartered in United States

When did Liquidia go public?

Liquidia's initial public offering (IPO) was on 26 July 2018

Is Liquidia in the S&P 500?

No, Liquidia is not included in the S&P 500 index

Is Liquidia in the NASDAQ 100?

No, Liquidia is not included in the NASDAQ 100 index

Is Liquidia in the Dow Jones?

No, Liquidia is not included in the Dow Jones index

When was Liquidia's last earnings report?

Liquidia's most recent earnings report was on 11 November 2024

When does Liquidia report earnings?

The next expected earnings date for Liquidia is 13 March 2025

Should I buy Liquidia stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions